Work

Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons

Year: 2021

Type: editorial

Source: Journal of Thoracic and Cardiovascular Surgery

DOI: 10.1016/j.jtcvs.2021.02.008

Authors: David R. Jones, Yi-Long Wu, Masahiro Tsuboi, Roy S. Herbst

Institutions: Memorial Sloan Kettering Cancer Center, Guangdong Provincial People's Hospital, National Cancer Center Hospital East, Yale Cancer Center, Yale University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Roche, Boehringer Ingelheim, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma, Cancer Center Support Grant, Yale Clinical and Translational Science Award

OpenAlex ID: W3126351292

Cites: 15

Cited by: 9

Related to: 10